Investors House reported Q1 revenues of EUR 1.6m, 4% below our 1.
MODI reported sales growth in Q1’24 of 31%, confirming that the strong momentum seen in H2’23 carrie...
Fortsatt god tillväxt och lönsamhet Efter ett rekordstarkt 2023 med en tillväxt på 134% inledde Mave...
Redeye gives an initial take on the news that IRLAB has entered into a development cooperation with ...
Redeye comments on G5’s Q1-results where topline was softer than expected while solid profitability,...
Sales-2% and adj. EBITA +11% vs. ABGSCe Stunning 9.
Redeye updates on Nepa following the Q1 results which showed continued hesitation from clients hurti...
Redeye updates its estimates after reviewing Truecaller's Q1 report, which showed higher sales and p...
Redeye makes upward estimate revisions on the back of I-Tech’s solid Q1 figures.
Redeye provides an update following Optomed’s FDA clearance for Aurora AEYE and the company’s Q1 rep...
Taaleri's Q1 2024 results were well above LSEG Data & Analytics consensus and our expectations, driv...
NoHo Partners' Q1 2024 results were largely in line with Vara Research consensus expectations.
Redeye comments on Better Collective ahead of Q1-results (due 21 May after market close) where M&A w...
Redeye leaves a short note following Magle’s announcement yesterday of the initial outcome of the pu...
Q1 EBITDA NOK -6m vs ABGSCe of NOK -1m, Q2 likely weaker New targets more achievable - sales +22% in...
Q1 EBITDA of USD 13.0m, slightly below ABGSCe Small downwards revisions to estimates after Q1 P/NAV ...
25% organic growth, 13% ARR growth y-o-y Slightly higher opex offset by better gross margin Trading ...
Sales 5% vs. ABGSCe, adj. EBITA 7% vs. ABGSCe No material estimate changes Trading at 9-6x EV/EBITA ...
Q1'24 results due 14 May 207% growth y-o-y, but limited sequential growth EBIT revised up 2% for '24...
1% organic sales growth y-o-y Profitability impressed in Q1, ability to offset wage increases We mak...
